MacroGenics, Inc.
MGNXNext catalyst
lorigerlimab
Androgen-Independent Prostatic Cancer
Get an email about MGNX's next catalysts
Track MacroGenics (MGNX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
MGNX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.10 | FQ end Sep/2026 | Call: tbd
Lorigerlimab Phase 2 Est. Readout
Estimated primary completion for Lorigerlimab trial (NCT06730347) in Platinum-resistant Ovarian Cancer. Topline data typically follows completion by weeks to months.
SourceHow MGNX's past catalysts played out
Market Overview
Stock performance and key metrics
Tebotelimab
Gastric Cancer
Teplizumab
Type 1 Diabetes Mellitus
Margetuximab
HER-2 Positive Breast Cancer
Retifanlimab
Gastric Cancer
vobramitamab duocarmazine (Arm A)
Castration-Resistant Prostatic Cancer
MGD007 + MGA012
Colorectal Cancer Metastatic
lorigerlimab
Androgen-Independent Prostatic Cancer
Enoblituzumab
Prostate Cancer
MGC018
Extensive-stage Small-cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tebotelimab | Phase 3 | Gastric Cancer | - | - |
Teplizumab | Phase 3 | Type 1 Diabetes Mellitus | - | - |
Margetuximab | Phase 3 | HER-2 Positive Breast Cancer | - | - |
Retifanlimab | Phase 3 | Gastric Cancer | - | - |
vobramitamab duocarmazine (Arm A) | Phase 2 | Castration-Resistant Prostatic Cancer | - | - |
MGD007 + MGA012 | Phase 2 | Colorectal Cancer Metastatic | - | - |
lorigerlimab | Phase 2 | Androgen-Independent Prostatic Cancer | - | - |
Enoblituzumab | Phase 2 | Prostate Cancer | - | - |
MGC018 | Phase 2 | Extensive-stage Small-cell Lung Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in MacroGenics, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in MacroGenics, Inc.'s (MGNX) pipeline across Phase 3, Phase 2. Its lead program is Margetuximab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MacroGenics, Inc.'s next FDA catalyst?→
MacroGenics, Inc.'s (MGNX) next tracked catalyst is a Phase 2 readout expected July 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MGNX biotech catalysts?→
Add MGNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MacroGenics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.